Description of use

Stratipath Breast is an EU regulatory compliant solution for risk stratification of invasive breast cancer using AI-based precision diagnostics to analyse breast cancer tissue, enabling identification of patients with increased risk of disease progression. Stratipath Breast uses state-of-the-art AI to analyse images from H&E-stained tissue sections of resected breast tumours to detect cancer and stratify intermediate risk tumours (e.g. NHG 2) into low- and high-risk groups, based on grade-related tumour morphology. The risk stratification is based on a rigorous scientific development process and validation using multi-source real-world datasets, comprising histopathology images and associated clinical outcome data.